Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

1885studies indexed841with human data111registered trials1630carry a numeric findingLibrarian added 33 studies today
Showing 1885 studiesSortNewest indexed
C
grade
Synergistic antibacterial and osteogenic properties of micro-arc oxidation GO@Ag/SF composite coatings for the repair of infectious bone defects.
CJC-1295 without DAC (Modified GRF 1-29) · Bioactive materials · 2026 · Animal study · Preclinical
The GO@Ag/SF composite coating shows promise for enhancing antibacterial and osteogenic outcomes in bone defects, but human studies are needed to confirm its clinical utility.
Inhibition rates against S. aureus and E. coli were up to 98.3 ± 1.2%.
B
grade
Real-world outcomes of [<sup>177</sup>Lu]Lu-PSMA-I&T in [<sup>18</sup>F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.
Vipivotide · European journal of nuclear medicine and molecular imaging · 2026 · Observational · n=25
Higher [68Ga]Ga-PSMA-11 SUVmean and SUVmean ratio may predict PSA response in [18F]FDG-positive mCRPC patients, but further research is needed.
PSA30 response in 44% of patients.
B
grade
Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [<sup>177</sup>Lu]Lu-PSMA-617 or [<sup>177</sup>Lu]Lu-PSMA-I&T therapy: dosimetry results.
Vipivotide · European journal of nuclear medicine and molecular imaging · 2026 · Observational · n=50
ARSi did not significantly enhance tumor absorbed doses in mCRPC patients receiving [177Lu]Lu-PSMA therapies. Larger studies are needed to confirm these findings.
2.1 ± 4.0 Gy/GBq vs 1.5 ± 1.7 Gy/GBq for [177Lu]Lu-PSMA-617, p=0.24
B
grade
Evaluation of [<sup>225</sup>Ac]Ac-PSMA-617 vis-a-vis Rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 PRLT Versus Cabazitaxel or Oral Metronomic Chemotherapy in mCRPC: An Observational Analysis of Outcome and Toxicity Profiles in a Real-World Clinical Scenario.
Vipivotide · The Prostate · 2026 · Observational · n=66
[225Ac]Ac-PSMA-617 shows promise for mCRPC with better survival and manageable toxicity, but further trials are needed.
PSA decline of >50% and disease control rate of 60% in [225Ac]Ac-PSMA-617 patients.
C
grade
Mechanoregulating HA-integrated anisotropic fibrous vessel promote AKT-sensitive and YAP-associated endothelial responses and improve regional lymphatic drainage in lymphedema.
MGF (Mechano Growth Factor) · Biomaterials · 2026 · Animal study · Preclinical
A hyaluronic acid-integrated fibrous scaffold shows promise in improving lymphatic function in a rat model of lymphedema, but human studies are needed to confirm its clinical relevance.
Reduced ankle swelling in a rat lymphedema model.
Showing 25 of 1885